Skip to main content
Top
Published in: Drugs & Aging 7/2007

01-07-2007 | Therapy In Practice

Epidemiology and Management of Apathy in Patients with Alzheimer’s Disease

Authors: Romina Mizrahi, Prof. Sergio E. Starkstein

Published in: Drugs & Aging | Issue 7/2007

Login to get access

Abstract

Although apathy is a diagnostic term used with increasing frequency in both neurology and psychiatry, confusion still exists as to its proper definition and assessment, and whether apathy should be considered a symptom of major psychiatric diseases or an independent syndrome in its own right. Moreover, critical questions regarding the phenomenology and clinical correlates of apathy and the syndromic validity of this construct still exist. Despite these nosological concerns, there is strong evidence that apathy is a common finding in Alzheimer’s disease (AD). However, the treatment of apathy is still elusive. Current data are obtained from randomised controlled trials that did not investigate apathy per se, but rather a number of other behavioural and psychological variables. In this context, acetylcholinesterase inhibitors and psychosocial interventions are the only available modalities for treating apathy in AD with some efficacy.
Literature
1.
go back to reference Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991; 3(3): 243–54PubMed Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991; 3(3): 243–54PubMed
2.
go back to reference Starkstein SE. Apathy and withdrawal. Int Psychogeriatr 2000; 12Suppl. 1: 135–8CrossRef Starkstein SE. Apathy and withdrawal. Int Psychogeriatr 2000; 12Suppl. 1: 135–8CrossRef
3.
go back to reference van Reekum R, Stuss DT, Ostrander L. Apathy: why care? J Neuropsychiatry Clin Neurosci 2005; 17(1): 7–19PubMedCrossRef van Reekum R, Stuss DT, Ostrander L. Apathy: why care? J Neuropsychiatry Clin Neurosci 2005; 17(1): 7–19PubMedCrossRef
4.
go back to reference Marin RS, Wilkosz PA. Disorders of diminished motivation. J Head Trauma Rehabil 2005; 20(4): 377–88PubMedCrossRef Marin RS, Wilkosz PA. Disorders of diminished motivation. J Head Trauma Rehabil 2005; 20(4): 377–88PubMedCrossRef
5.
go back to reference Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cerebral Cortex 2006; 16(7): 916–28PubMedCrossRef Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cerebral Cortex 2006; 16(7): 916–28PubMedCrossRef
6.
go back to reference American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association, 1994 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association, 1994
7.
go back to reference World Health Organization (WHO). The ICD-10 classification of mental and behavioural disorders. Geneva: WHO, 1993 World Health Organization (WHO). The ICD-10 classification of mental and behavioural disorders. Geneva: WHO, 1993
8.
go back to reference Marin RS. Differential diagnosis and classification of apathy. Am J Psychiatry 1990; 147(1): 22–30PubMed Marin RS. Differential diagnosis and classification of apathy. Am J Psychiatry 1990; 147(1): 22–30PubMed
9.
go back to reference Starkstein SE, Fedoroff JP, Price TR, et al. Apathy following cerebrovascular lesions. Stroke 1993; 24(11): 1625–30PubMedCrossRef Starkstein SE, Fedoroff JP, Price TR, et al. Apathy following cerebrovascular lesions. Stroke 1993; 24(11): 1625–30PubMedCrossRef
10.
go back to reference Starkstein SE, Mayberg HS, Preziosi TJ, et al. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1992; 4(2): 134–9PubMed Starkstein SE, Mayberg HS, Preziosi TJ, et al. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1992; 4(2): 134–9PubMed
11.
go back to reference Starkstein SE, Migliorelli R, Manes F, et al. The prevalence and clinical correlates of apathy and irritability in Alzheimer’s disease. Eur J Neurol 1995; 2: 540–6CrossRef Starkstein SE, Migliorelli R, Manes F, et al. The prevalence and clinical correlates of apathy and irritability in Alzheimer’s disease. Eur J Neurol 1995; 2: 540–6CrossRef
12.
go back to reference Starkstein SE, Merello M. Psychiatric and cognitive disorders in Parkinson’s disease. Cambridge: Cambridge University Press, 2002CrossRef Starkstein SE, Merello M. Psychiatric and cognitive disorders in Parkinson’s disease. Cambridge: Cambridge University Press, 2002CrossRef
13.
go back to reference Starkstein SE, Petracca G, Chemerinski E, et al. Syndromic validity of apathy in Alzheimer’s disease. Am J Psychiatry 2001; 158(6): 872–7PubMedCrossRef Starkstein SE, Petracca G, Chemerinski E, et al. Syndromic validity of apathy in Alzheimer’s disease. Am J Psychiatry 2001; 158(6): 872–7PubMedCrossRef
14.
go back to reference Levy ML, Cummings JL, Fairbanks LA, et al. Apathy is not depression. J Neuropsychiatry Clin Neurosci 1998; 10(3): 314–9PubMed Levy ML, Cummings JL, Fairbanks LA, et al. Apathy is not depression. J Neuropsychiatry Clin Neurosci 1998; 10(3): 314–9PubMed
15.
go back to reference Starkstein SE, Garau ML, Cao A. Prevalence and clinical correlates of disinhibition in dementia. Cogn Behav Neurol 2004; 17: 139–47PubMedCrossRef Starkstein SE, Garau ML, Cao A. Prevalence and clinical correlates of disinhibition in dementia. Cogn Behav Neurol 2004; 17: 139–47PubMedCrossRef
16.
go back to reference Buettner L, Fitzsimmons S. Mixed behaviors in dementia: the need for a paradigm shift. J Gerontol Nurs 2006; 32(7): 15–22PubMed Buettner L, Fitzsimmons S. Mixed behaviors in dementia: the need for a paradigm shift. J Gerontol Nurs 2006; 32(7): 15–22PubMed
17.
go back to reference Marin RS, Butters MA, Mulsant BH, et al. Apathy and executive function in depressed elderly. J Geriatr Psychiatry Neurol 2003; 16(2): 112–6PubMedCrossRef Marin RS, Butters MA, Mulsant BH, et al. Apathy and executive function in depressed elderly. J Geriatr Psychiatry Neurol 2003; 16(2): 112–6PubMedCrossRef
18.
go back to reference Marin RS, Firinciogullari S, Biedrzycki RC. Group differences in the relationship between apathy and depression. J Nerv Ment Dis 1994; 182(4): 235–9PubMedCrossRef Marin RS, Firinciogullari S, Biedrzycki RC. Group differences in the relationship between apathy and depression. J Nerv Ment Dis 1994; 182(4): 235–9PubMedCrossRef
19.
go back to reference Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997; 48Suppl. 6: S10–6PubMedCrossRef Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997; 48Suppl. 6: S10–6PubMedCrossRef
20.
go back to reference Strauss ME, Sperry SD. An informant-based assessment of apathy in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol 2002; 15(3): 176–83PubMed Strauss ME, Sperry SD. An informant-based assessment of apathy in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol 2002; 15(3): 176–83PubMed
21.
go back to reference Robert PH, Clairet S, Benoit M, et al. The Apathy Inventory: assessment of apathy and awareness in Alzheimer’s disease, Parkinson’s disease and mild cognitive impairment. Int J Geriatr Psychiatry 2002; 17(12): 1099–105PubMedCrossRef Robert PH, Clairet S, Benoit M, et al. The Apathy Inventory: assessment of apathy and awareness in Alzheimer’s disease, Parkinson’s disease and mild cognitive impairment. Int J Geriatr Psychiatry 2002; 17(12): 1099–105PubMedCrossRef
22.
go back to reference Starkstein SE, Ingram L, Garau LM, et al. On the overlap between apathy and depression in dementia. J Neurol Neurosurg Psychiatry 2005; 76: 1070–4PubMedCrossRef Starkstein SE, Ingram L, Garau LM, et al. On the overlap between apathy and depression in dementia. J Neurol Neurosurg Psychiatry 2005; 76: 1070–4PubMedCrossRef
23.
go back to reference Spitzer RL, Williams JB, Gibbon M, et al. The Structured Clinical Interview for DSM-III-R (SCID): I. History, rationale, and description. Arch Gen Psychiatry 1992; 49(8): 624–9PubMedCrossRef Spitzer RL, Williams JB, Gibbon M, et al. The Structured Clinical Interview for DSM-III-R (SCID): I. History, rationale, and description. Arch Gen Psychiatry 1992; 49(8): 624–9PubMedCrossRef
24.
go back to reference Tatsch MF, Bottino CM, Azevedo D, et al. Neuropsychiatric symptoms in Alzheimer disease and cognitively impaired, nondemented elderly from a community-based sample in Brazil: prevalence and relationship with dementia severity. Am J Geriatr Psychiatry 2006; 14(5): 438–45PubMedCrossRef Tatsch MF, Bottino CM, Azevedo D, et al. Neuropsychiatric symptoms in Alzheimer disease and cognitively impaired, nondemented elderly from a community-based sample in Brazil: prevalence and relationship with dementia severity. Am J Geriatr Psychiatry 2006; 14(5): 438–45PubMedCrossRef
25.
go back to reference Landes AM, Sperry SD, Strauss ME. Prevalence of apathy, dysphoria, and depression in relation to dementia severity in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 2005; 17(3): 342–9PubMedCrossRef Landes AM, Sperry SD, Strauss ME. Prevalence of apathy, dysphoria, and depression in relation to dementia severity in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 2005; 17(3): 342–9PubMedCrossRef
26.
go back to reference Craig D, Mirakhur A, Hart DJ, et al. A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer’s disease. Am J Geriatr Psychiatry 2005; 13(6): 460–8PubMed Craig D, Mirakhur A, Hart DJ, et al. A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer’s disease. Am J Geriatr Psychiatry 2005; 13(6): 460–8PubMed
27.
go back to reference Thomas P, Clement JP, Hazif-Thomas C, et al. Family, Alzheimer’s disease and negative symptoms. Int J Geriatr Psychiatry 2001; 16(2): 192–202PubMedCrossRef Thomas P, Clement JP, Hazif-Thomas C, et al. Family, Alzheimer’s disease and negative symptoms. Int J Geriatr Psychiatry 2001; 16(2): 192–202PubMedCrossRef
28.
go back to reference Starkstein SE, Jorge R, Mizrahi R, et al. A prospective longitudinal study of apathy in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2006 Jan; 77(1): 8–11PubMedCrossRef Starkstein SE, Jorge R, Mizrahi R, et al. A prospective longitudinal study of apathy in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2006 Jan; 77(1): 8–11PubMedCrossRef
29.
go back to reference Boyle PA, Malloy PF, Salloway S, et al. Executive dysfunction and apathy predict functional impairment in Alzheimer disease. Am J Geriatr Psychiatry 2003; 11(2): 214–21PubMed Boyle PA, Malloy PF, Salloway S, et al. Executive dysfunction and apathy predict functional impairment in Alzheimer disease. Am J Geriatr Psychiatry 2003; 11(2): 214–21PubMed
30.
go back to reference Robert PH, Berr C, Volteau M, et al. Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer’s disease: a one-year follow-up study. Clin Neurol Neurosurg 2006; 108(8): 733–6PubMedCrossRef Robert PH, Berr C, Volteau M, et al. Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer’s disease: a one-year follow-up study. Clin Neurol Neurosurg 2006; 108(8): 733–6PubMedCrossRef
31.
go back to reference Ready RE, Ott BR, Grace J, et al. Apathy and executive dysfunction in mild cognitive impairment and Alzheimer disease. Am J Geriatr Psychiatry 2003; 11(2): 222–8PubMed Ready RE, Ott BR, Grace J, et al. Apathy and executive dysfunction in mild cognitive impairment and Alzheimer disease. Am J Geriatr Psychiatry 2003; 11(2): 222–8PubMed
32.
go back to reference Robert PH, Berr C, Volteau M, et al. Neuropsychological performance in mild cognitive impairment with and without apathy. Dement Geriatr Cogn Disord 2006; 21(3): 192–7PubMedCrossRef Robert PH, Berr C, Volteau M, et al. Neuropsychological performance in mild cognitive impairment with and without apathy. Dement Geriatr Cogn Disord 2006; 21(3): 192–7PubMedCrossRef
33.
go back to reference Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000; 157(1): 4–15PubMed Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000; 157(1): 4–15PubMed
34.
go back to reference Cummings JL, Nadel A, Masterman D, et al. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer’s disease. J Geriatr Psychiatry Neurol 2001; 14(2): 101–8PubMedCrossRef Cummings JL, Nadel A, Masterman D, et al. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer’s disease. J Geriatr Psychiatry Neurol 2001; 14(2): 101–8PubMedCrossRef
35.
go back to reference Cummings JL, Koumaras B, Chen M, et al. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer’s disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 2005; 3(3): 137–48PubMedCrossRef Cummings JL, Koumaras B, Chen M, et al. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer’s disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 2005; 3(3): 137–48PubMedCrossRef
36.
go back to reference Herrmann N, Rabheru K, Wang J, et al. Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry 2005; 13(6): 527–34PubMed Herrmann N, Rabheru K, Wang J, et al. Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry 2005; 13(6): 527–34PubMed
37.
go back to reference Mega MS, Dinov ID, Porter V, et al. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Arch Neurol 2005; 62(5): 721–8PubMedCrossRef Mega MS, Dinov ID, Porter V, et al. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Arch Neurol 2005; 62(5): 721–8PubMedCrossRef
38.
go back to reference Kaufer D, Cummings JL, Christine D. Differential neuropsychiatric symptom responses to tacrine in Alzheimer’s disease: relationship to dementia severity. J Neuropsychiatry Clin Neurosci 1998; 10(1): 55–63PubMed Kaufer D, Cummings JL, Christine D. Differential neuropsychiatric symptom responses to tacrine in Alzheimer’s disease: relationship to dementia severity. J Neuropsychiatry Clin Neurosci 1998; 10(1): 55–63PubMed
39.
go back to reference Galynker I, Ieronimo C, Miner C, et al. Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci 1997; 9(2): 231–9PubMed Galynker I, Ieronimo C, Miner C, et al. Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci 1997; 9(2): 231–9PubMed
40.
go back to reference Andreasen NC. Methods for assessing positive and negative symptoms. Mod Probl Pharmacopsychiatry 1990; 24: 73–88PubMed Andreasen NC. Methods for assessing positive and negative symptoms. Mod Probl Pharmacopsychiatry 1990; 24: 73–88PubMed
41.
go back to reference Deb S, Crownshaw T. The role of pharmacotherapy in the management of behaviour disorders in traumatic brain injury patients. Brain Inj 2004; 18(1): 1–31PubMedCrossRef Deb S, Crownshaw T. The role of pharmacotherapy in the management of behaviour disorders in traumatic brain injury patients. Brain Inj 2004; 18(1): 1–31PubMedCrossRef
42.
go back to reference Watanabe MD, Martin EM, DeLeon OA, et al. Successful methylphenidate treatment of apathy after subcortical infarcts. J Neuropsychiatry Clin Neurosci 1995; 7(4): 502–4PubMed Watanabe MD, Martin EM, DeLeon OA, et al. Successful methylphenidate treatment of apathy after subcortical infarcts. J Neuropsychiatry Clin Neurosci 1995; 7(4): 502–4PubMed
44.
go back to reference Erkulwater S, Pillai R. Amantadine and the end-stage dementia of Alzheimer’s type. South Med J 1989; 82(5): 550–4PubMedCrossRef Erkulwater S, Pillai R. Amantadine and the end-stage dementia of Alzheimer’s type. South Med J 1989; 82(5): 550–4PubMedCrossRef
45.
go back to reference Chapman SB, Weiner MF, Rackley A, et al. Effects of cognitive-communication stimulation for Alzheimer’s disease patients treated with donepezil. J Speech Lang Hear Res 2004; 47(5): 1149–63PubMedCrossRef Chapman SB, Weiner MF, Rackley A, et al. Effects of cognitive-communication stimulation for Alzheimer’s disease patients treated with donepezil. J Speech Lang Hear Res 2004; 47(5): 1149–63PubMedCrossRef
46.
go back to reference Holmes C, Knights A, Dean C, et al. Keep music live: music and the alleviation of apathy in dementia subjects. Int Psychogeriatr 2006; 18(4): 623–30PubMedCrossRef Holmes C, Knights A, Dean C, et al. Keep music live: music and the alleviation of apathy in dementia subjects. Int Psychogeriatr 2006; 18(4): 623–30PubMedCrossRef
47.
go back to reference Verkaik R, van Weert JC, Francke AL. The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: a systematic review. Int J Geriatr Psychiatry 2005; 20(4): 301–14PubMedCrossRef Verkaik R, van Weert JC, Francke AL. The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: a systematic review. Int J Geriatr Psychiatry 2005; 20(4): 301–14PubMedCrossRef
48.
go back to reference Politis AM, Vozzella S, Mayer LS, et al. A randomized, controlled, clinical trial of activity therapy for apathy in patients with dementia residing in long-term care. Int J Geriatr Psychiatry 2004; 19(11): 1087–94PubMedCrossRef Politis AM, Vozzella S, Mayer LS, et al. A randomized, controlled, clinical trial of activity therapy for apathy in patients with dementia residing in long-term care. Int J Geriatr Psychiatry 2004; 19(11): 1087–94PubMedCrossRef
49.
go back to reference Overshott R, Byrne J, Burns A. Nonpharmacological and pharmacological interventions for symptoms in Alzheimer’s disease. Expert Rev Neurother 2004; 4(5): 809–21PubMedCrossRef Overshott R, Byrne J, Burns A. Nonpharmacological and pharmacological interventions for symptoms in Alzheimer’s disease. Expert Rev Neurother 2004; 4(5): 809–21PubMedCrossRef
50.
go back to reference Boyle PA, Malloy PF. Treating apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord 2004; 17(1–2): 91–9PubMedCrossRef Boyle PA, Malloy PF. Treating apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord 2004; 17(1–2): 91–9PubMedCrossRef
Metadata
Title
Epidemiology and Management of Apathy in Patients with Alzheimer’s Disease
Authors
Romina Mizrahi
Prof. Sergio E. Starkstein
Publication date
01-07-2007
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 7/2007
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200724070-00003

Other articles of this Issue 7/2007

Drugs & Aging 7/2007 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.